Adiponectin in renal disease – a review of the evidence as a risk factor for cardiovascular and all-cause mortality

References

• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
   PubMed Web of Science ®Google Scholar
• Friedman JM. A tale of two hormones. Nat Med 2010;16:1100–1106.
   PubMed Web of Science ®Google Scholar
• Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–26749.
   PubMed Web of Science ®Google Scholar
• Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–10703.
   PubMed Web of Science ®Google Scholar
• Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286–289.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996;120:803–812.
   PubMed Web of Science ®Google Scholar
• Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152–12162.
   PubMed Web of Science ®Google Scholar
• Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways. FEBS Lett 2010;584:4280–4286.
   PubMed Web of Science ®Google Scholar
• Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004;101:10308–10313.
   PubMed Web of Science ®Google Scholar
• Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010;120:4342–4352.
   PubMed Web of Science ®Google Scholar
• Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84–89.
   PubMed Web of Science ®Google Scholar
• Holland WL, Miller RA, Wang ZV et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011;17:55–63.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T. Adiponectin receptor signaling: a new layer to the current model. Cell Metab 2011;13:123–124.
   PubMedGoogle Scholar
• Teoh H, Quan A, Bang KW et al. Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab 2008;295:E658–E664.
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Quan A et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010;299:H656–H663.
   Google Scholar
• Ley SH, Harris SB, Connelly PW et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008;31:1410–1415.
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Hanley AJ, Connelly PW, Maguire G, Sermer M, Zinman B. Low serum levels of high-molecular weight adiponectin in Indo-Asian women during pregnancy: evidence of ethnic variation in adiponectin isoform distribution. Diabetes Care 2006;29:1377–1379.
   PubMed Web of Science ®Google Scholar
• Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 2008;149:2270–2282.
   PubMed Web of Science ®Google Scholar
• Sinha MK, Songer T, Xiao Q et al. Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clin Chem 2007;53:2144–2151.
   PubMedGoogle Scholar
• Bluher M, Brennan AM, Kelesidis T et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007;30:280–285.
   PubMed Web of Science ®Google Scholar
• Gavrila A, Chan JL, Yiannakouris N et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003;88:4823–4831.
   PubMed Web of Science ®Google Scholar
• Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003;88:2838–2843.
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–1599.
   PubMed Web of Science ®Google Scholar
• Calvani M, Scarfone A, Granato L et al. Restoration of adiponectin pulsatility in severely obese subjects after weight loss. Diabetes 2004;53:939–947.
   PubMed Web of Science ®Google Scholar
• Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 2007;56:2174–2177.
   PubMed Web of Science ®Google Scholar
• Semple RK, Halberg NH, Burling K et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007;56:1712–1717.
   PubMed Web of Science ®Google Scholar
• Barnes MM, Curran-Everett D, Hamman RF et al. Determinants of adiponectin levels in young people with Type 1 diabetes. Diabet Med 2008;25:365–369.
   PubMedGoogle Scholar
• Adamczak M, Czerwienska B, Chudek J, Wiecek A. Renal extraction of circulating adiponectin in patients with renovascular hypertension. Acta Physiol Hung 2007;94:143–148.
   PubMedGoogle Scholar
• Hosokawa Y, Yamada Y, Obata Y et al. Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients. Clin Exp Nephrol 2011.
   PubMedGoogle Scholar
• Komura N, Kihara S, Sonoda M et al. Increment and impairment of adiponectin in renal failure. Cardiovasc Res 2010;86:471–477.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Iwatani H, Kihara S et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007;27:1910–1917.
   PubMed Web of Science ®Google Scholar
• Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008;118:1645–1656.
   PubMed Web of Science ®Google Scholar
• Ahima RS. Linking adiponectin to proteinuria. J Clin Invest 2008;118:1619–1622.
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Doulgerakis D, Moyssakis I et al. Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 2004;36:721–727.
   PubMed Web of Science ®Google Scholar
• Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005;20:129–134.
   PubMed Web of Science ®Google Scholar
• Pilz S, Mangge H, Wellnitz B et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006;91:4277–4286.
   PubMedGoogle Scholar
• Hara K, Uchida T, Takebayashi K et al. Determinants of serum high molecular weight (HMW) adiponectin levels in patients with coronary artery disease: associations with cardio-renal-anemia syndrome. Intern Med 2011;50:2953–2960.
   PubMedGoogle Scholar
• Inoue T, Kotooka N, Morooka T et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007;100:569–574.
   PubMed Web of Science ®Google Scholar
• Hajer GR, van der Graaf Y, Olijhoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J 2007;154:750–757.
   PubMedGoogle Scholar
• Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756–1762.
   PubMed Web of Science ®Google Scholar
• Pilz S, Maerz W, Weihrauch G et al. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2006;364:251–255.
   PubMed Web of Science ®Google Scholar
• George J, Patal S, Wexler D et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006;92:1420–1424.
   PubMedGoogle Scholar
• Cavusoglu E, Ruwende C, Chopra V et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006;27:2300–2309.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Tanaka T, Sakai H et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007;28:1723–1730.
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007;165:164–174.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Whincup PH, Lennon L SattarN. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Int Med 2007;167:1510–1517.
   PubMedGoogle Scholar
• Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005;16:1091–1098.
   PubMed Web of Science ®Google Scholar
• Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279–1286.
   PubMedGoogle Scholar
• Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599–2606.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134–141.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Tripepi G, Cambareri F et al. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 2005;15:125–130.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Postorino M, Marino C, Pizzini P, Cutrupi S, Tripepi G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med 2011;269:172–181.
   PubMedGoogle Scholar
• Takemoto F, Katori H, Sawa N et al. Plasma adiponectin: a predictor of coronary heart disease in hemodialysis patients--a Japanese prospective eight-year study. Nephron Clin Pract 2009;111:c12–c20.
   Google Scholar
• Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008;23:2619–2628.
   PubMedGoogle Scholar
• Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004;43:1047–1055.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Hashimoto T, Kobayashi H et al. Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol Dial Transplant 2006;21:1640–1647.
   PubMedGoogle Scholar
• Lim PS, Hu CY, Wu MY, Wu TK, Chang HC. Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis. Nephrology (Carlton) 2007;12:546–552.
   PubMedGoogle Scholar
• Chudek J, Adamczak M, Karkoszka H et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003;35:2186–2189.
   PubMed Web of Science ®Google Scholar
• Bayes B, Lauzurica R, Granada ML et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004;78:26–30.
   PubMed Web of Science ®Google Scholar
• Bayes B, Granada ML, Pastor MC et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007;7:416–422.
   PubMedGoogle Scholar
• Nishimura K, Kishikawa H, Kato T et al. Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis. Transpl Int 2009;22:694–701.
   PubMedGoogle Scholar
• Yilmaz MI, Saglam M, Caglar K et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005;80:1660–1666.
   PubMed Web of Science ®Google Scholar
• Bakkaloglu SA, Soylemezoglu O, Buyan N et al. Adiponectin levels and arteriosclerotic risk factors in pediatric renal transplant recipients. Pediatr Transplant 2006;10:187–192.
   PubMedGoogle Scholar
• Hjelmesaeth J, Flyvbjerg A, Jenssen T et al. Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. Clin J Am Soc Nephrol 2006;1:575–582.
   PubMed Web of Science ®Google Scholar
• Shehab-Eldin W, Shoker A. Predictors of new onset of diabetes after transplantation in stable renal recipients. Nephron Clin Pract 2008;110:c1–c9.
   Google Scholar
• Prasad GVR, Vorobeichik L, Nash MM, Huang M, Rapi LMG et al. Lower total and percent of high-molecular-weight adiponectin concentration in south Asian kidney transplant recipients. Clin Kidney J 2012;5:124–129.
   PubMedGoogle Scholar
• Canas L, Bayes B, Granada ML et al. Is adiponectin a marker of preclinical atherosclerosis in kidney transplantation? Clin Transplant 2011.
   PubMedGoogle Scholar
• Hayashi M, Shibata R, Takahashi H et al. Association of adiponectin with carotid arteriosclerosis in predialysis chronic kidney disease. Am J Nephrol 2011;34:249–255.
   PubMedGoogle Scholar
• Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004;65:274–281.
   PubMed Web of Science ®Google Scholar
• Saraheimo M, Forsblom C, Fagerudd J et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005;28:1410–1414.
   PubMed Web of Science ®Google Scholar
• Saraheimo M, Forsblom C, Thorn L et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008;31:1165–1169.
   PubMedGoogle Scholar
• Hadjadj S, Aubert R, Fumeron F et al. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 2005;48:1088–1092.
   PubMedGoogle Scholar
• Koshimura J, Fujita H, Narita T et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 2004;316:165–169.
   PubMed Web of Science ®Google Scholar
• Looker HC, Krakoff J, Funahashi T et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004;89:4010–4017.
   PubMedGoogle Scholar
• Shen YY, Hughes JT, Charlesworth JA, Kelly JJ, Peake PW. Adiponectin is present in the urine in its native conformation, and specifically reduces the secretion of MCP-1 by proximal tubular cells. Nephrology (Carlton) 2008;13:405–410.
   PubMed Web of Science ®Google Scholar
• von Eynatten M, Liu D, Hock C et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 2009;58:2093–2099.
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006;91:129–135.
   PubMedGoogle Scholar
• Fernandez M, Triplitt C, Wajcberg E et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008;31:121–127.
   PubMed Web of Science ®Google Scholar
• Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009;24:1876–1883.
   PubMed Web of Science ®Google Scholar
• Yenicesu M, Yilmaz MI, Caglar K et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005;99:c115–c121.
   Google Scholar
• Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 2007;30:239–244.
   PubMedGoogle Scholar
• Fujita H, Morii T, Koshimura J et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006;53:745–752.
   PubMedGoogle Scholar
• Yilmaz MI, Saglam M, Qureshi AR et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008;23:1621–1627.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Tarnow L, Frystyk J et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008;74:649–654.
   PubMedGoogle Scholar
• Forsblom C, Thomas MC, Moran J et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 2011;270:346–355.
   PubMed Web of Science ®Google Scholar
• Makinen VP, Forsblom C, Thorn LM et al. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 2008;57:2480–2487.
   PubMed Web of Science ®Google Scholar
• Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009;76:567–575.
   PubMedGoogle Scholar
• Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec M. Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule. Clin Appl Thromb Hemost 2008;14:338–345.
   PubMedGoogle Scholar
• Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004;89:4620–4627.
   PubMedGoogle Scholar
• Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients. Am J Nephrol 2005;25:203–210.
   PubMedGoogle Scholar
• Tsukamoto O, Fujita M, Kato M et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070–2077.
   PubMed Web of Science ®Google Scholar
• Aso Y, Suganuma R, Wakabayashi S et al. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. Transl Res 2009;154:175–182.
   PubMedGoogle Scholar
• Seow KM, Lin YH, Hwang JL et al. Expression levels of haem oxygenase-1 in the omental adipose tissue and peripheral blood mononuclear cells of women with polycystic ovary syndrome. Hum Reprod 2011;26:431–437.
   Google Scholar
• Shakeri-Manesch S, Zeyda M, Huber J, Ludvik B, Prager G, Stulnig TM. Diminished upregulation of visceral adipose heme oxygenase-1 correlates with waist-to-hip ratio and insulin resistance. Int J Obes (Lond) 2009;33:1257–1264.
   PubMed Web of Science ®Google Scholar
• Shen YY, Charlesworth JA, Kelly JJ, Peake PW. The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007;56:1201–1208.
   PubMedGoogle Scholar
• Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007;22:171–178.
   PubMedGoogle Scholar
• Wanner C, Krane V. Sunrise of statins after AURORA and 4D? J Am Soc Nephrol 2011;22:1184–1186.
   PubMedGoogle Scholar
• Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–248.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181–2192.
   PubMed Web of Science ®Google Scholar